Kahraman, SedaErul, EnesSeyyar, MustafaGumusay, OzgeBayram, ErtugrulDemirel, Burcin CakanAcar, OmerAksoy, SercanBaytemur, Naziyet KoseSahin, ElifCabuk, DevrimBasaran, GulPaydas, SemraYaren, ArzuGuven, Deniz CanErdogan, Atike PinarDemirci, UmutYasar, AlperBayoglu, Ibrahim VedatHizal, MutluGulbagci, BurcuPaksoy, NailDavarci, Sena EceYilmaz, FundaDogan, OzlemOrhan, Sibel OyucuKayikcioglu, ErkanAytac, AliKeskinkilic, MerveMocan, Eda EylemerUnal, Olcun UmitAydin, EsraYucel, HakanIsik, DenizEren, OnderUluc, Basak OyanOzcelik, MelikeHacibekiroglu, IlhanAydiner, AdnanDemir, HacerOksuzoglu, BernaCilbir, EbruCubukcu, ErdemCetin, BulentOktay, EsinErol, CihanOkutur, Sadi KeremYildirim, NilgunAlkan, AliSelcukbiricik, FatihAksoy, AsudeKarakas, YusufOzkanli, GulhanDuman, Berna BozkurtAydin, DincerDulgar, OzgecanEr, Muhammed MuhiddinTeker, FatihYavuzsen, TugbaAykan, Musa BarisInal, AliIriagac, YakupKalkan, Nurhan OnalKeser, MuratSakalar, TeomanMenekse, SerkanKut, EnginBilgin, BurakKaraoglanoglu, MugeSunar, VeliOzdemir, OzlemTurhal, Nazim SerdarKaradurmus, NuriYalcin, BulentSendur, Mehmet Ali Nahit2024-10-072024-10-072023-05-031479-6694https://doi.org/10.2217/fon-2022-1287https://www.tandfonline.com/doi/full/10.2217/fon-2022-1287https://hdl.handle.net/11452/45952Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.eninfo:eu-repo/semantics/closedAccessCdk 46 inhibitorsHer2-negative metastatic breast cancerHr-positiveLetrozoleOncologyArticle00099164670000110.2217/fon-2022-1287